```html

Zebra Pattern Dermatitis

Overview

Zebra pattern dermatitis (also called zebra‑striped eczema or linear papular dermatitis) is a rare, chronic inflammatory skin disorder characterized by alternating hyperpigmented and hypopigmented linear streaks that resemble the coat of a zebra. The condition most often appears on the extremities, trunk, or buttocks, and may be associated with itching, scaling, or mild pain.

The exact prevalence is difficult to determine because many cases go undiagnosed or are mis‑classified as other forms of eczema. Current estimates from dermatology registries in the United States and Europe suggest an incidence of 0.03–0.07 cases per 100,000 persons per year (NIH, 2020). It typically presents in young adults (15–35 years) but can occur at any age, including childhood.

Both sexes are affected, though a slight male predominance (≈55 %) has been reported (Cleveland Clinic). The condition is more common in individuals of Northern European ancestry, possibly reflecting genetic susceptibility.

Symptoms

Symptoms may vary from subtle discoloration to widespread, bothersome lesions. The most frequent findings include:

• Linear, alternating pigmented bands (dark‑brown to black vs. pink‑white) that follow Blaschko’s lines.
• Pruritus (itching) – usually mild to moderate; scratching can cause secondary excoriation.
• Fine scaling or flaking over the hyperpigmented strips.
• Dryness (xerosis) of the surrounding skin.
• Mild burning or stinging sensation, especially after heat exposure or sweating.
• Hyperkeratotic papules – small raised bumps that may appear where the dark bands are most intense.
• Transient swelling (edema) of the affected area during flare‑ups.
• Rare systemic symptoms such as low‑grade fever or malaise, usually indicating secondary infection.

Unlike some other dermatoses, zebra pattern dermatitis rarely involves mucous membranes, nails, or the scalp.

Causes and Risk Factors

Underlying Mechanisms

The pathogenesis is not fully understood, but research highlights three main contributors:

1. Genetic mosaicism – Mutations in skin‑specific genes (e.g., KRT1, FLG) that occur after fertilization may create lines of cells with altered melanin production, generating the characteristic striped appearance (Mayo Clinic).
2. Immune dysregulation – A Th2‑dominant immune response, similar to atopic dermatitis, leads to chronic inflammation and barrier dysfunction.
3. Environmental triggers – Heat, humidity, friction, and certain chemicals can exacerbate inflammation and pigment changes.

Risk Factors

• Personal or family history of atopic dermatitis, asthma, or allergic rhinitis.
• Genetic predisposition (first‑degree relatives with unexplained linear skin markings).
• Occupations with repetitive friction (e.g., athletes, manual laborers).
• Exposure to irritants such as detergents, solvents, or certain cosmetics.
• Living in humid climates where sweating is frequent.

Diagnosis

Because the presentation can mimic other linear dermatoses (e.g., linear lichen planus, vitiligo, or post‑inflammatory hyperpigmentation), a systematic approach is essential.

Clinical Evaluation

• History taking: onset, progression, itch severity, family skin disease, occupational exposures.
• Physical exam: pattern of lesions, distribution along Blaschko’s lines, presence of scaling or papules.

Diagnostic Tests

• Dermatoscopy – reveals alternating pigment networks and subtle vascular patterns.
• Skin biopsy (punch 4 mm): Histology shows focal epidermal hyperkeratosis, spongiosis, and a superficial perivascular lymphocytic infiltrate, with melanin incontinence limited to hyperpigmented segments.
• Patch testing – to rule out contact dermatitis when an irritant trigger is suspected.
• Genetic testing – not routine, but next‑generation sequencing can identify somatic mutations when the diagnosis is uncertain.

Diagnosis is primarily clinical; biopsy is reserved for atypical cases or when malignancy must be excluded.

Treatment Options

Therapy aims to reduce inflammation, restore barrier function, and minimize pigment contrast. Treatment is individualized based on disease severity and patient tolerance.

Topical Medications

• Low‑ to mid‑potency corticosteroids (e.g., hydrocortisone 2.5%, triamcinolone 0.1%) applied twice daily for 2–4 weeks during flares.
• Topical calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%); useful for steroid‑sparing, especially on the face or intertriginous areas.
• Barrier repair creams containing ceramides, hyaluronic acid, or urea 10% to improve hydration.

Systemic Therapies

• Antihistamines (cetirizine 10 mg daily) for pruritus control.
• Oral corticosteroids (prednisone ≤ 0.5 mg/kg) for severe, acute exacerbations; taper within 2–3 weeks to avoid rebound.
• Biologic agents – Dupilumab (300 mg subcutaneously every 2 weeks) has shown benefit in case series by targeting IL‑4/IL‑13 pathways involved in atopic inflammation (CDC, 2023).
• Janus kinase (JAK) inhibitors – oral upadacitinib or baricitinib may be